Bortezomib

Overview

Bortezomib (brand name Velcade) is a first-in-class reversible proteasome inhibitor approved by the FDA in 2003 for multiple myeloma and in 2006 for mantle cell lymphoma. Although often grouped pedagogically with peptide therapeutics because of its boronic dipeptide architecture, bortezomib is technically a peptide-boronate small molecule. It revolutionized multiple myeloma therapy, combining with dexamethasone and immunomodulatory drugs (lenalidomide, pomalidomide) to dramatically extend overall survival in relapsed/refractory and newly diagnosed disease.

Its introduction spawned a proteasome inhibitor class that now includes carfilzomib and oral ixazomib.

Structure / Sequence

Bortezomib is the dipeptide boronic acid [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid. The boronate warhead forms a covalent tetrahedral adduct with the active-site threonine of the proteasome. The pyrazine cap and leucine-phenylalanine mimicking residues drive chymotrypsin-like subsite specificity.

Mechanism of Action

The 26S proteasome degrades ubiquitinated intracellular proteins and is central to regulation of cell-cycle progression, NF-kB signaling, and the unfolded protein response. Bortezomib reversibly binds the chymotrypsin-like (beta-5) subunit of the 20S proteasome, with secondary activity on the caspase-like (beta-1) subunit. In myeloma cells, which rely on high protein turnover to manage immunoglobulin synthesis, proteasome inhibition triggers ER stress, unfolded protein response activation, and apoptosis via both intrinsic and extrinsic pathways.

Bortezomib also suppresses NF-kB activation by stabilizing IkB, contributing to antitumor and anti-inflammatory effects.

Research Summary

Pharmacokinetics

Bortezomib is administered IV bolus or subcutaneously (the SC route reduces neuropathy). Peak proteasome inhibition occurs within 5 minutes and recovers with a biphasic distribution phase. The terminal half-life is 40 to 193 hours. Metabolism proceeds primarily through hepatic CYP3A4, CYP2C19, and CYP1A2 mediated oxidative deboronation; strong CYP3A4 inhibitors require caution.

Dosing Protocols

• Multiple myeloma: 1.3 mg/m2 subcutaneously or IV bolus on days 1, 4, 8, and 11 of a 21-day cycle
• Weekly dosing: 1.3 or 1.6 mg/m2 on days 1, 8, 15, 22 of a 35-day cycle (used in transplant-ineligible patients to reduce neuropathy)
• Mantle cell lymphoma (VR-CAP): 1.3 mg/m2 on days 1, 4, 8, 11 of 21-day cycles

Subcutaneous administration is preferred over IV in most regimens because it produces equivalent efficacy with significantly less peripheral neuropathy.

Common Discussion Topics

• Peripheral neuropathy prevention with SC dosing and weekly schedules
• Herpes zoster reactivation and need for antiviral prophylaxis
• Role in VRd induction before autologous stem cell transplant
• Resistance mechanisms including beta-5 subunit mutations and proteasome upregulation
• Transition of patients to carfilzomib on relapse

Related Compounds

• Carfilzomib — irreversible proteasome inhibitor
• Enfuvirtide — peptide-based antiretroviral
• Bivalirudin — synthetic peptide anticoagulant
• Daptomycin — lipopeptide antibiotic